Nanoparticles and nanoscale drug delivery systems (for materials such as small molecules, genetic material and other APIs) have become a significant part of the medical industry’s product research and development focus and the demand for nanoparticle-based medicines and therapies has exploded in recent years. The COVID-19 pandemic catapulted mRNA-based therapeutics into the forefront of life science, realizing the benefits of collaborative global efforts for unprecedented drug development.

There is a clear need for automated, effective and efficient production of LNPs for screening, optimization and manufacturing. We recognise that rapid product development requires acceleration and parallel task execution, and scalability and automation are key to address both requirements. Microfluidics is central to achieving scalability and quality issues that traditional methods cannot address.

Microfluidics controls particle size, achieves excellent monodispersity and encapsulation efficiency. Particle integrity is preserved and damage caused by mechanical forces is avoided. Particle Works has developed 4 core platforms to meet the various demands of the drug discovery journey, and using our reusable microfluidics chips ensures that our process technology is scalable across the whole of your drug development pipeline.

Using the same microfluidic chips and pumping technology at every stage of nanoparticle development ensures your formulations are transferrable and scalable right through from discovery, through development to scale-up and manufacturing.

We are on a journey together. From our game-changing screening platform ALiS – the first to bring automation and high-throughput screening to the marketplace; to the ANP System – a unique, comprehensive and flexible single system for both process optimization and continuous production; to Pilot – our scale-up system; our innovative, pioneering technologies offer the complete solution for our customers’ drug development pipeline.